CY1114575T1 - Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του - Google Patents

Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του

Info

Publication number
CY1114575T1
CY1114575T1 CY20131100313T CY131100313T CY1114575T1 CY 1114575 T1 CY1114575 T1 CY 1114575T1 CY 20131100313 T CY20131100313 T CY 20131100313T CY 131100313 T CY131100313 T CY 131100313T CY 1114575 T1 CY1114575 T1 CY 1114575T1
Authority
CY
Cyprus
Prior art keywords
solution
hydroxy
dimetoxy
aceton
preparation procedure
Prior art date
Application number
CY20131100313T
Other languages
Greek (el)
English (en)
Inventor
Eric Didier
Marc-Antoine Perrin
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114575(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of CY1114575T1 publication Critical patent/CY1114575T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
CY20131100313T 2003-09-19 2013-04-16 Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του CY1114575T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0311016A FR2859996B1 (fr) 2003-09-19 2003-09-19 Solvat acetonique du dimethoxy docetaxel et son procede de preparation
EP04787385A EP1667986B1 (fr) 2003-09-19 2004-09-16 Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (1)

Publication Number Publication Date
CY1114575T1 true CY1114575T1 (el) 2016-10-05

Family

ID=34224354

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100313T CY1114575T1 (el) 2003-09-19 2013-04-16 Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του
CY2013016C CY2013016I2 (el) 2003-09-19 2013-05-13 Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2013016C CY2013016I2 (el) 2003-09-19 2013-05-13 Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του

Country Status (37)

Country Link
US (1) US7241907B2 (OSRAM)
EP (1) EP1667986B1 (OSRAM)
JP (1) JP5010279B2 (OSRAM)
KR (1) KR101123588B1 (OSRAM)
CN (1) CN100429207C (OSRAM)
AR (1) AR045667A1 (OSRAM)
AU (1) AU2004274212B2 (OSRAM)
BE (1) BE2013C036I2 (OSRAM)
BR (1) BRPI0414492A8 (OSRAM)
CA (1) CA2539309A1 (OSRAM)
CR (1) CR8292A (OSRAM)
CY (2) CY1114575T1 (OSRAM)
DK (1) DK1667986T3 (OSRAM)
ES (1) ES2403149T4 (OSRAM)
FR (2) FR2859996B1 (OSRAM)
HR (1) HRP20130322T1 (OSRAM)
HU (1) HUS1300025I1 (OSRAM)
IL (1) IL174240A (OSRAM)
LU (1) LU92172I2 (OSRAM)
MA (1) MA28045A1 (OSRAM)
ME (2) MEP11708A (OSRAM)
MX (1) MXPA06002639A (OSRAM)
MY (1) MY136668A (OSRAM)
NO (2) NO335997B1 (OSRAM)
NZ (1) NZ545835A (OSRAM)
PA (1) PA8612401A1 (OSRAM)
PE (1) PE20050870A1 (OSRAM)
PL (1) PL1667986T3 (OSRAM)
PT (1) PT1667986E (OSRAM)
RS (2) RS54614B1 (OSRAM)
RU (1) RU2342373C2 (OSRAM)
SI (1) SI1667986T1 (OSRAM)
TN (1) TNSN06086A1 (OSRAM)
TW (1) TWI382022B (OSRAM)
UA (1) UA87115C2 (OSRAM)
WO (1) WO2005028462A1 (OSRAM)
ZA (1) ZA200602255B (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160653A1 (en) * 2006-03-21 2010-06-24 Dr. Reddy's Laboratories Ltd. Docetaxel polymorphs and processes
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
FR2945211A1 (fr) * 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
CA2708489A1 (en) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
EA024186B1 (ru) * 2009-10-29 2016-08-31 Авентис Фарма С.А. Применение кабазитаксела в комбинации с преднизоном или преднизолоном для лечения рака простаты
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012142117A1 (en) 2011-04-12 2012-10-18 Plus Chemicals Sa Solid state forms of cabazitaxel and processes for preparation thereof
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
WO2013072766A2 (en) 2011-10-31 2013-05-23 Scinopharm Taiwan, Ltd. Process for cabazitaxel and intermediates thereof
EP2773629B1 (en) 2011-11-01 2018-04-11 Fresenius Kabi Oncology Limited Process for the preparation of an amorphous form of cabazitaxel
DE112012004944T5 (de) 2011-11-28 2014-12-11 Fresenius Kabi Oncology Ltd. Kristalline Formen von Cabazitaxel und deren Herstellungsverfahren
EP2791122B1 (en) 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
WO2013111157A1 (en) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
BR112014019675A2 (pt) * 2012-02-10 2017-07-11 Aventis Pharma Sa usos pediátricos de cabazitaxel
EP2822932A2 (en) 2012-03-08 2015-01-14 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
WO2014022237A1 (en) 2012-07-31 2014-02-06 Yung Shin Pharm. Ind. Co., Ltd. Amorphous cabazitaxel
EP2884963B1 (en) 2012-08-15 2017-12-27 Yung Shin Pharm. Ind. Co. Ltd. Stable pharmaceutical formulation of cabazitaxel
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015000165A1 (zh) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
CN104277014A (zh) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
EP2865675A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
ES2904505T3 (es) 2015-01-12 2022-04-05 Emcure Pharmaceuticals Ltd Formulación líquida de cabazitaxel
WO2016133387A1 (en) 2015-02-17 2016-08-25 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7148533B2 (ja) 2016-11-29 2022-10-05 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピプテリン及びその塩の多形
BR112020003865A8 (pt) 2017-09-01 2022-08-16 Censa Pharmaceuticals Inc Composições farmacêuticas compreendendo sepiapterina e seus usos
MX2020012979A (es) 2018-05-30 2021-04-29 Ptc Therapeutics Mp Inc Métodos para aumentar la exposición al plasma de sepiapterina.
US12257252B2 (en) 2018-05-30 2025-03-25 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
DE4425978C1 (de) * 1994-07-22 1995-11-23 Karlsruhe Forschzent Verfahren zur Herstellung keramischer Mikrostrukturen
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
PT1178979E (pt) * 1999-05-17 2004-04-30 Bristol Myers Squibb Co Novas condicoes de reaccao para a clivagem de eteres de sililo na preparacao de paclitaxel (taxol(r)) e analogos de paclitaxel
TWI333856B (en) * 2001-11-29 2010-12-01 Daiichi Seiyaku Co Crystals of taxane and process for their production

Also Published As

Publication number Publication date
BE2013C036I2 (OSRAM) 2023-12-14
MEP11708A (en) 2010-06-10
US20050065138A1 (en) 2005-03-24
UA87115C2 (ru) 2009-06-25
NO2015013I1 (no) 2015-05-04
AU2004274212A1 (en) 2005-03-31
KR101123588B1 (ko) 2012-03-22
CR8292A (es) 2008-10-15
BRPI0414492A (pt) 2006-11-14
LU92172I2 (fr) 2013-05-21
AU2004274212B2 (en) 2010-03-04
ES2403149T4 (es) 2013-06-24
MXPA06002639A (es) 2006-06-05
RS20060189A (en) 2008-06-05
CN100429207C (zh) 2008-10-29
FR13C0037I1 (fr) 2013-09-08
FR2859996A1 (fr) 2005-03-25
US7241907B2 (en) 2007-07-10
CN1849311A (zh) 2006-10-18
CY2013016I1 (el) 2018-01-10
RS54614B1 (en) 2016-08-31
DK1667986T3 (da) 2013-05-06
NO20061714L (no) 2006-04-19
JP2007505866A (ja) 2007-03-15
EP1667986B1 (fr) 2013-01-16
ES2403149T3 (es) 2013-05-14
NO335997B1 (no) 2015-04-20
CY2013016I2 (el) 2018-01-10
AR045667A1 (es) 2005-11-02
JP5010279B2 (ja) 2012-08-29
LU92172I9 (OSRAM) 2019-01-03
FR2859996B1 (fr) 2006-02-03
ZA200602255B (en) 2007-07-25
MY136668A (en) 2008-11-28
SI1667986T1 (sl) 2013-05-31
WO2005028462A1 (fr) 2005-03-31
BRPI0414492A8 (pt) 2019-01-15
PT1667986E (pt) 2013-04-24
HUS1300025I1 (hu) 2016-08-29
HK1093340A1 (zh) 2007-03-02
ME00054B (me) 2011-02-10
KR20060072147A (ko) 2006-06-27
EP1667986A1 (fr) 2006-06-14
TW200524891A (en) 2005-08-01
PA8612401A1 (es) 2005-08-04
FR13C0037I2 (fr) 2015-11-20
IL174240A0 (en) 2006-08-01
NO2015013I2 (no) 2015-04-22
RU2342373C2 (ru) 2008-12-27
MA28045A1 (fr) 2006-07-03
PE20050870A1 (es) 2005-11-21
CA2539309A1 (fr) 2005-03-31
TWI382022B (zh) 2013-01-11
PL1667986T3 (pl) 2013-06-28
TNSN06086A1 (en) 2007-10-03
NZ545835A (en) 2009-10-30
IL174240A (en) 2010-12-30
HRP20130322T1 (en) 2013-07-31
RU2006113122A (ru) 2006-08-27

Similar Documents

Publication Publication Date Title
CY1114575T1 (el) Διαλυμα ακετονης διμεθοξυ δοσεταξελης και η διαδικασια παρασκευης του
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1118231T1 (el) Συνθεση λιποσωματος
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
UY28572A1 (es) Compuestos novedosos
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
EA200702551A1 (ru) Способ получения эпоксида из хлоргидрина
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1111524T1 (el) Νεα συντηγμενα πυρρολοκαρβαζολια
CY1113789T1 (el) Συνδυασμοι απο ενεργοποιητες διαυλων καλιου και αναστολεις διαυλων νατριου ή δραστικες ουσιες που επηρεαζουν τους διαυλους νατριου για τη θεραπεια επωδυνων καταστασεων
EA201001024A1 (ru) Обработка растений банана и картофеля с помощью новой противогрибковой композиции
NO20034660D0 (no) Spiropyrazolforbindelser
EA200802111A1 (ru) Имплантаты для лечения состояний, ассоциируемых с допамином
ATE468317T1 (de) Herstellung von 1,3-diphenylprop-2-en-1- onderivaten
NO20063293L (no) Farmasoytiske forbindelser
CY1108226T1 (el) Αντικαρκινικες ενωσεις βασισμενες σε καχαλαλιδης f
CY1112607T1 (el) Εντομοκτονοι συνδυασμοι που περιλαμβανουν αβαμεκτινη και κυφλουμετοφενη
EA200870058A1 (ru) Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран
CY1105813T1 (el) Φαρμακευτικοι συνδυασμοι που βασιζονται σε παραγωγα πυριδοϊνδολονης και σε αντικαρκινικα μεσα
DK1633373T3 (da) Farmaceutisk sammensætning indeholdende glucan hidrørende fra mikroalger
EP4393415A4 (en) WOVEN SINGLE RIVET DEGRADABLE IMPLANT INSTRUMENT